JP6232184B2 - 神経伝導速度改善のための方法および組成物 - Google Patents

神経伝導速度改善のための方法および組成物 Download PDF

Info

Publication number
JP6232184B2
JP6232184B2 JP2012549209A JP2012549209A JP6232184B2 JP 6232184 B2 JP6232184 B2 JP 6232184B2 JP 2012549209 A JP2012549209 A JP 2012549209A JP 2012549209 A JP2012549209 A JP 2012549209A JP 6232184 B2 JP6232184 B2 JP 6232184B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydrogen
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012549209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517300A5 (enExample
JP2013517300A (ja
Inventor
トーマス デイビッド マッカーシー
トーマス デイビッド マッカーシー
アンドリュー レインズフォード ベイカー
アンドリュー レインズフォード ベイカー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013517300A publication Critical patent/JP2013517300A/ja
Publication of JP2013517300A5 publication Critical patent/JP2013517300A5/ja
Application granted granted Critical
Publication of JP6232184B2 publication Critical patent/JP6232184B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012549209A 2010-01-19 2011-01-19 神経伝導速度改善のための方法および組成物 Expired - Fee Related JP6232184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29637510P 2010-01-19 2010-01-19
US61/296,375 2010-01-19
PCT/AU2011/000051 WO2011088504A1 (en) 2010-01-19 2011-01-19 Methods and compositions for improved nerve conduction velocity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016073914A Division JP2016155846A (ja) 2010-01-19 2016-04-01 神経伝導速度改善のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2013517300A JP2013517300A (ja) 2013-05-16
JP2013517300A5 JP2013517300A5 (enExample) 2014-02-27
JP6232184B2 true JP6232184B2 (ja) 2017-11-15

Family

ID=44306296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549209A Expired - Fee Related JP6232184B2 (ja) 2010-01-19 2011-01-19 神経伝導速度改善のための方法および組成物
JP2016073914A Pending JP2016155846A (ja) 2010-01-19 2016-04-01 神経伝導速度改善のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016073914A Pending JP2016155846A (ja) 2010-01-19 2016-04-01 神経伝導速度改善のための方法および組成物

Country Status (10)

Country Link
US (1) US9095587B2 (enExample)
EP (1) EP2525795B1 (enExample)
JP (2) JP6232184B2 (enExample)
CN (2) CN102821765A (enExample)
AU (1) AU2011207104C1 (enExample)
CA (1) CA2787173C (enExample)
ES (1) ES2560327T3 (enExample)
NZ (1) NZ601383A (enExample)
WO (1) WO2011088504A1 (enExample)
ZA (1) ZA201205375B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028620T2 (en) 2010-07-21 2016-12-28 Novartis Ag Tetrahydroisoquinoline derivative salt and solvates
US10391331B2 (en) * 2011-03-29 2019-08-27 Biolyst, Llc. Systems and methods for use in treating sensory impairment
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
PT2807171T (pt) 2012-01-25 2020-11-03 Novartis Ag Compostos heterocíclicos e métodos para a sua utilização
NZ627560A (en) 2012-01-25 2016-08-26 Novartis Ag Heterocyclic piperazine compounds and methods for their use
CN105358532B (zh) * 2013-07-08 2019-07-23 诺华股份有限公司 杂环化合物和它们的使用方法
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体
WO2016142867A1 (en) 2015-03-12 2016-09-15 Novartis Ag Heterocyclic compounds and methods for their use
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
EP3620454B1 (en) 2017-06-09 2021-05-05 Shandong Danhong Pharmaceutical Co., Ltd. Carboxylic acid derivative as at2r receptor antagonist
CN112585120B (zh) * 2018-11-02 2022-11-11 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091390A (en) 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
CA2132544C (en) * 1992-04-13 2005-10-18 Frank Carey Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
EP1830869B1 (en) * 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists

Also Published As

Publication number Publication date
HK1176554A1 (en) 2013-08-02
AU2011207104C1 (en) 2015-10-08
JP2016155846A (ja) 2016-09-01
AU2011207104B2 (en) 2015-07-02
ES2560327T3 (es) 2016-02-18
ZA201205375B (en) 2013-09-25
CN102821765A (zh) 2012-12-12
AU2011207104A1 (en) 2012-07-26
EP2525795B1 (en) 2015-10-21
EP2525795A1 (en) 2012-11-28
CA2787173A1 (en) 2011-07-28
NZ601383A (en) 2014-07-25
CA2787173C (en) 2018-05-01
US9095587B2 (en) 2015-08-04
EP2525795A4 (en) 2013-07-24
WO2011088504A1 (en) 2011-07-28
US20130131103A1 (en) 2013-05-23
JP2013517300A (ja) 2013-05-16
CN107744519A (zh) 2018-03-02

Similar Documents

Publication Publication Date Title
JP6232184B2 (ja) 神経伝導速度改善のための方法および組成物
KR102722949B1 (ko) 신경근 장애의 치료에 사용하기 위한 화합물
WO1992014453A1 (en) Compositions and methods of treatment of sympathetically maintained pain
JP2006501265A5 (enExample)
AU3182400A (en) N-(2-hydroxy-3-(1-piperidinyl)propoxy)pyridine-1-oxide-3- carboximidoyl chloride and its use in the treatment of insulin resistance
WO2005030221A1 (ja) 加齢黄斑変性治療剤
JPH05506035A (ja) 眼痛治療用組成物
CZ284441B6 (cs) Použití 4-aminopyridinu k výrobě léčiva pro léčbu neurologického stavu
Takahara et al. Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model
US20210322510A1 (en) Oxytocin improves treatment of obstructive sleep apnea
US8106099B2 (en) Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias
JP4658919B2 (ja) フェニルカルボン酸アミドおよびＩＫｒチャンネル遮断剤の組み合わせならびに心房性不整脈を処置するためのその使用
TW200403066A (en) New uses of substituted aminoalkanephosphonic acids
Hibbs et al. Agents acting at the neuromuscular junction and autonomic ganglia
HK1176554B (en) Methods and compositions for improved nerve conduction velocity
WO1997038691A1 (en) Remedy for retinal neuropathy
CN106999449A (zh) 用于治疗多汗症的方法
JP5583325B2 (ja) イオンチャネル調節化合物の投与レジメ
JP2007505036A (ja) フェニルカルボキサミドとβ−アドレナリン性受容体遮断剤の組み合わせおよびそれらの心房性不整脈の処置のための使用
Eldin Anesthetic Management Of Patients With Myopathies
Ugawa et al. Acid-sensing ion channels and pain: therapeutic potential?
CN121240861A (zh) 食欲素2受体激动剂用于改善睡眠期间呼吸功能的用途
Whalen et al. Periventricular anteroventral third ventricle lesions diminish the pressor response produced by systemic injection of the N-methyl-d-aspartate receptor antagonist MK-801
Manjunath A Comparative Evaluation of Intravenous Dexmedetomidine and Oral Clonidine in Attenuating the Rise in Intra Ocular Pressure Following Administration of Suxamethonium, Laryngoscopy and Intubation
US20110269805A1 (en) Method of treating sensorimotor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150604

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171023

R150 Certificate of patent or registration of utility model

Ref document number: 6232184

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees